Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab

Cancer Biomarkers

Volumn 14, Issue 4, 2014, Pages 259-265

  Koyama, N ^a,b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Adverse cardiovascular event; bevacizumab; non small cell lung cancer; survival benefit; vascular endothelial growth factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PEMETREXED; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVERSE OUTCOME; AGED; ALLERGY; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; HYPONATREMIA; KAPLAN MEIER METHOD; LIVER TOXICITY; LOSS OF APPETITE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84927173064     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140404     Document Type: Article

References (18)

1. C. G. Azzoli, S. Baker, Jr., S. Temin, W. Pao, T. Aliff, J. Brahmer, D. H. Johnson, J. L. Laskin, G. Masters, D. Milton, L. Nordquist, D. G. Pfister, S. Piantadosi, J. H. Schiller, R. Smith, T. J. Smith, J. R. Strawn, D. Trent and G. Giaccone, American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall- cell lung cancer, J Clin Oncol 27 (2009), 6251-66.
2. F. Barlesi, A. Scherpereel, A. Rittmeyer, A. Pazzola, N. Ferrer Tur, J. H. Kim, M. J. Ahn, J. G. Aerts, V. Gorbunova, A. Vikstrom, E. K. Wong, P. Perez-Moreno, L. Mitchell and H. J. Groen, Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089), J Clin Oncol 31 (2013), 3004-11.
3. M. H. Cohen, J. Gootenberg, P. Keegan and R. Pazdur, FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/ metastatic recurrent nonsquamous non-small cell lung cancer, Oncologist 12 (2007), 713-8.
4. S. E. Dahlberg, A. B. Sandler, J. R. Brahmer, J. H. Schiller and D. H. Johnson, Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599, J Clin Oncol 28 (2010), 949-54.
5. A. Dowlati, R. Gray, A. B. Sandler, J. H. Schiller and D. H. Johnson, Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study, Clin Cancer Res 14 (2008), 1407-12.
6. G. Dranitsaris, N. Beegle, A. Ravelo, T. Kalberer, E. Yu and S. Thomas, Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non-Small- Cell Lung Cancer, Clin Lung Cancer (2012).
7. T. Fleitas, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado, M. Martin, J. Gomez-Codina, J. Montalar and G. Reynes, VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer, Clin Transl Oncol (2013).
8. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med 350 (2004), 2335-42.
9. H. I. Hurwitz, P. S. Douglas, J. P. Middleton, G. W. Sledge, D. H. Johnson, D. A. Reardon, D. Chen and O. Rosen, Analysis of Early Hypertension and Clinical Outcome With Beva cizumab: Results From Seven Phase III Studies, Oncologist (2013).
10. D. H. Johnson, L. Fehrenbacher, W. F. Novotny, R. S. Herbst, J. J. Nemunaitis, D. M. Jablons, C. J. Langer, R. F. DeVore, 3rd, J. Gaudreault, L. A. Damico, E. Holmgren and F. Kabbinavar, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol 22 (2004), 2184-91.
11. S. Kilickap, H. Abali and I. Celik, Bevacizumab, bleeding, thrombosis, and warfarin, J Clin Oncol 21 (2003), 3542; author reply 3543.
12. Y. Nagai, H. Miyazawa, Huqun, T. Tanaka, K. Udagawa, M. Kato, S. Fukuyama, A. Yokote, K. Kobayashi, M. Kanazawa and K. Hagiwara, Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp, Cancer Res 65 (2005), 7276-82.
13. J. D. Patel, T. A. Hensing, A. Rademaker, E. M. Hart, M. G. Blum, D. T. Milton and P. D. Bonomi, Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer, J Clin Oncol 27 (2009), 3284-9.
14. J. D. Patel, M. A. Socinski, E. B. Garon, C. H. Reynolds, D. R. Spigel, M. R. Olsen, R. C. Hermann, R. M. Jotte, T. Beck, D. A. Richards, S. C. Guba, J. Liu, B. Frimodt-Moller, W. J. John, C. K. Obasaju, E. J. Pennella, P. Bonomi and R. Govindan, PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer, J Clin Oncol (2013).
15. M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore and C. Manegold, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol 27 (2009), 1227-34.
16. M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore and C. Manegold, Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol 21 (2010), 1804-9.
17. A. Sandler, R. Gray, M. C. Perry, J. Brahmer, J. H. Schiller, A. Dowlati, R. Lilenbaum and D. H. Johnson, Paclitaxelcarboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med 355 (2006), 2542-50.
18. D. C. Sane, L. Anton and K. B. Brosnihan, Angiogenic growth factors and hypertension, Angiogenesis 7 (2004), 193-201.